Earlier studies have identified a decrease in PPAR-γ mRNA [38] and protein expression in lungs from patients with pulmonary hypertension [6] while rosiglitazone, a PPAR-γ agonist, has been shown to attenuate hypoxia-induced pulmonary hypertension, vascular remodeling, and reactive oxygen species generation in the mouse lung [39], [40]. Here, PPARG is linked to pulmonary hypertension.